Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-27T01:22:32.219Z Has data issue: false hasContentIssue false
  • English
  • Français

Aborted sudden cardiac death in a young soldier with concomitant hypertrophic cardiomyopathy and Wolff–Parkinson–White syndrome

Part of: Basic Science

Published online by Cambridge University Press:  26 December 2018

Sunwon Kim Open the ORCID record for Sunwon Kim [Opens in a new window] ,
Woo Hyuk Song  and
Sung Soon Kim
Sunwon Kim
Affiliation:
Department of Cardiology, Korea University Ansan Hospital, Ansan, Republic of Korea
Woo Hyuk Song*
Affiliation:
Department of Cardiology, Korea University Ansan Hospital, Ansan, Republic of Korea
Sung Soon Kim
Affiliation:
Division of Cardiology, Department of Internal Medicine, The Armed Forces Capital Hospital, Seongnam, Republic of Korea
*
Author for correspondence: W. H. Song, MD, PhD, Department of Cardiology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Republic of Korea. Tel: 82 31 412 6558, Fax: 82 31 8099 6352; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

We present a young soldier presenting with aborted sudden cardiac death, who was found to have concomitant hypertrophic cardiomyopathy and Wolff–Parkinson–White syndrome. Along with pathological haemodynamic features of hypertrophic cardiomyopathy, an easily-inducible re-entrant tachycardia was clearly documented in our patient. Given the fatal potential of supraventricular tachycardia in hypertrophic cardiomyopathy, we postulated that his tachyarrhythmia could potentially trigger the event. Upon his refusal to receive implantable cardioverter/defibrillator therapy, we ablated anatomical arrhythmogenic substrate instead, and he remained uneventfully over 3 years on β-blocker.

Keywords

Sudden cardiac deathventricular fibrillationhypertrophic cardiomyopathyWolff–Parkinson–White syndromeimplantable cardioverter defibrillator
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 2 , February 2019 , pp. 252 - 255
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Kim S, Song WH, Kim SS. (2018) Aborted sudden cardiac death in a young soldier with concomitant hypertrophic cardiomyopathy and Wolff–Parkinson–White syndrome. Cardiology in the Young page 252 of 255. doi: 10.1017/S1047951118002123

References

1. Porto, AG, Brun, F, Severini, GM, et al. Clinical spectrum of PRKAG2 syndrome. Circ Arrhythmia Electrophysiol 2016; 9: e003121.Google Scholar
2. Kimura, A, Harada, H, Park, JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997; 16: 379–382.Google Scholar
3. Bobkowski, W, Sobieszczanska, M, Turska-Kmiec, A, et al. Mutation of the MYH7 gene in a child with hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. J Appl Genet 2007; 48: 185–188.Google Scholar
4. Authors/Task Force, Elliott, PM, Anastasakis, A, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.Google Scholar
5. Munclinger, MJ, Thornton, AS, Schutte, DP, Sliwa, K. Fatal potential of supraventricular tachycardia in hypertrophic cardiomyopathy. Int J Cardiol 2004; 93: 335–337.Google Scholar
6. Stafford, WJ, Trohman, RG, Bilsker, M, Zaman, L, Castellanos, A, Myerburg, RJ. Cardiac-arrest in an adolescent with atrial-fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7: 701–704.Google Scholar
7. Elliott, PM, Sharma, S, Varnava, A, Poloniecki, J, Rowland, E, McKenna, WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596–1601.Google Scholar
8. McKenna, WJ, Behr, ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87: 169–176.Google Scholar
9. Priori, SG, Blomstrom-Lundqvist, C, Mazzanti, A, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793–2867.Google Scholar
10. Lin, G, Nishimura, RA, Gersh, BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009; 95: 709–714.Google Scholar
11. Thomas, SA, Friedmann, E, Kao, CW, et al. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care: Official Publ Am Assoc Crit Care Nurses 2006; 15: 389–398.Google Scholar
12. Lampert, R, Salberg, L, Burg, M. Emotional stress triggers symptoms in hypertrophic cardiomyopathy: a survey of the hypertrophic cardiomyopathy association. Pacing Clin Electrophysiol 2010; 33: 1047–1053.Google Scholar
Supplementary material: File

Kim et al. supplementary material

Kim et al. supplementary material 1

Download Kim et al. supplementary material(File)
File 544.5 KB